prbd News

Press Releases for US Biosimilar Market

715

Gain a Deep Insight into the Global Healthcare Cold Chain Logistic Services Market

Driven by a strong demand of biopharmaceuticals, vaccines and clinical trial materials; the global market for healthcare cold chain logistic services is expected to grow exponentially in the coming years.
By : | 03-12-2012 | Health and Fitness:Healthcare | Total Views : 715
1351

Biosimilar Insulin Products in the US to Grow at a CAGR of 74 Percent over the Period 2013-2020

Lantus is expected to be the most lucrative target for biosimilar manufacturers and account for 71% of the total biosimilar Insulin sales by 2020.
By : | 01-25-2012 | Industry:Industry | Total Views : 1351
568

The Penetration of Biosimilars in the US Will Vary Across Different Biological Classes

The volume penetration of biosimilars in the US will strongly depend upon the complexity of the molecule, the patient pool that it caters and the extent of savings it brings to payers and providers
By : | 01-12-2012 | Health and Fitness:Health and Fitness | Total Views : 568
854

New Report Suggests that Roche is Less Exposed to Biosimilars than Amgen

Excluding Mabthera, Roche’s other brands will face biosimilar competition only after 2019. As a result, the company will suffer most of its brand erosion post-2020.
By : | 11-29-2011 | Medical:Medical | Total Views : 854
630

Biosimilars for Blood Disorder Indications in the US Will Reach More Than US$ 2.4 Billion in 2020

Biosimilar versions of Epogen (Epoetin Alfa) may be launched as early as 2013. This launch is expected to be followed by launches of biosimilar versions of Neupogen (Filgrastim) and Neulasta (Pegfilgrastim).
By : | 11-17-2011 | Business:Markets | Total Views : 630
741

The Market for Biosimilars Will be a Marathon and Not a Sprint

A new report from IMARC Group expects the US biosimilar market to reach revenues worth US$ 11.4 Billion by 2020. This market, however, unlike small molecule generics, is expected to be a marathon and not a sprint.
By : | 07-27-2011 | Health and Fitness:Health and Fitness | Total Views : 741

Page 1 of 1

TOP 10 PR Updates

Press Releases for US Biosimilar Market

Gain a Deep Insight into the Global Healthcare Cold Chain Logistic Services Market

Biosimilar Insulin Products in the US to Grow at a CAGR of 74 Percent over the Period 2013-2020

The Penetration of Biosimilars in the US Will Vary Across Different Biological Classes

New Report Suggests that Roche is Less Exposed to Biosimilars than Amgen

Biosimilars for Blood Disorder Indications in the US Will Reach More Than US$ 2.4 Billion in 2020

The Market for Biosimilars Will be a Marathon and Not a Sprint

TOP 10 PR Updates